Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals.

Shields CL, Dalvin LA, Chang M, Mazloumi M, Fortin P, McGarrey M, Martin A, Yaghy A, Yang X, Vichitvejpaisal P, Mashayekhi A, Shields JA.

JAMA Ophthalmol. 2019 Dec 12. doi: 10.1001/jamaophthalmol.2019.5132. [Epub ahead of print]

PMID:
31830238
2.

Uveal metastasis in 1111 patients: Interval to metastasis and overall survival based on timing of primary cancer diagnosis.

Welch RJ, Malik K, Mayro EL, Newman JH, Honig SE, Ang SM, Selzer EB, Acaba-Berrocal LA, McGarrey MP, Graf AE, Considine SP, Shields JA, Shields CL.

Saudi J Ophthalmol. 2019 Jul-Sep;33(3):229-237. doi: 10.1016/j.sjopt.2019.07.006. Epub 2019 Jul 25.

3.

Choroidal amelanotic tumours: clinical differentiation of benign from malignant lesions in 5586 cases.

Welch RJ, Newman JH, Honig SE, Mayro EL, McGarrey M, Graf AE, Selzer EB, Acaba-Berrocal LA, Considine SP, Malik K, Shields JA, Shields CL.

Br J Ophthalmol. 2020 Feb;104(2):194-201. doi: 10.1136/bjophthalmol-2018-313680. Epub 2019 Apr 25.

PMID:
31023712
4.

Uveal Metastasis: Clinical Features and Survival Outcome of 2214 Tumors in 1111 Patients Based on Primary Tumor Origin.

Shields CL, Welch RJ, Malik K, Acaba-Berrocal LA, Selzer EB, Newman JH, Mayro EL, Constantinescu AB, Spencer MA, McGarrey MP, Knapp AN, Graf AE, Altman AJ, Considine SP, Shields JA.

Middle East Afr J Ophthalmol. 2018 Apr-Jun;25(2):81-90. doi: 10.4103/meajo.MEAJO_6_18.

Supplemental Content

Loading ...
Support Center